Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 948 2356

Website: kairospharma.com

Address:

2355 Westwood Boulevard, Suite 139, Los Angeles, United States

TrdrBuckNKy Feb. 9 at 9:10 PM

$KAPA I have been tough with my comments regarding this one, frustration and disappointment with recent results... However, it was pointed out to me of a grant by the DoD with the current administration, so, here's the link, read for yourself - it's encouraging - but it's coming up on a year and some news regarding such efforts/taxpayers input, would be appreciated at this point...I'll reach out to my congressman with an inquiry.... https://www.biospace.com/press-releases/kairos-pharma-ltd-announces-department-of-defense-grant-to-support-its-study-of-lead-compound-env105-to-prevent-drug-resistance-in-lung-cancer

1 · Reply

Everydayhustling Feb. 9 at 5:22 PM

$KAPA when is this thing gonna pop?

1 · Reply

Xtracked Feb. 8 at 7:19 PM

$KAPA Happy SBS! I'm east coast but fk the Pats right? Either way , I believe this is the week for news!:) The breadcrumbs lead to mid Feb.... It is time ...we have felt enough pain

1 · Reply

marione Feb. 6 at 8:14 PM

$KAPA BUY BUY BUY

0 · Reply

marione Feb. 6 at 8:02 PM

$FEED Beware of $KAPA, a long-term investment with high growth potential based on experimentation. Have you noticed that they were always buying in the premarket and aftermarket? We're on the verge of something new, with new developments and significant increases. KAIROS CLOSE TO +1000%++

0 · Reply

marione Feb. 6 at 7:58 PM

$KAPA $MSFT $AAPL $TSLA $AMZN Basandomi su 1 analista di Wall Street che ha offerto obiettivi di prezzo a 12 mesi per Kairos Pharma, Ltd. negli ultimi 3 mesi. L'obiettivo medio di prezzo è di 4,00 dollari con una previsione massima di 4,00 dollari e una minima di 4,00 dollari. L'obiettivo medio di prezzo rappresenta una variazione 515.67% rispetto all'ultimo prezzo di $0,65.

0 · Reply

marione Feb. 6 at 7:53 PM

$KAPA $MSFT $AAPL $TSLA $AMZN Beware of $KAPA, a long-term investment with high growth potential based on experimentation. Have you noticed that they were always buying in the premarket and aftermarket? We're on the verge of something new, with new developments and significant increases.

0 · Reply

GIPARK Feb. 6 at 10:17 AM

$KAPA 야!!!!! 어디가

0 · Reply

Oldshoe Feb. 5 at 11:24 PM

$KAPA Kapa most likely experienced a lot of short sells today. Ibkr inventory of shares available for loan (to short the stock) decreased by over 70k shares during regular hours. Some of that short share availability was likely reduced by people actually selling their own shares, it's also likely some shares were borrowed and sold short. Recent volume has been almost all small blocks, so reasonable to assume almost all recent trading has been retail (us uninformed traders). This is a speculative trade, highly likely it's somewhat tracking the current bitcoin drop. Kapa is thinly traded, can reverse upward just as easily as it went down. Not happy to see a drop but bullish long term, the trial data has been favorable so far. Opinion only.

0 · Reply

TB85 Feb. 5 at 7:57 PM

$KAPA I've had 5 new gray hairs, since we last got news. Maybe I'll go totaly bald on this. Sorry, I'll stop whining. But just one question, when news??

0 · Reply

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

Dec 17, 2025, 8:15 AM EST - 7 weeks ago

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Nov 4, 2025, 8:00 AM EST - 3 months ago

Kairos Pharma Provides Shareholder Update

Oct 20, 2025, 8:00 AM EDT - 4 months ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Sep 18, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 11, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 3, 2025, 8:15 AM EDT - 5 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 2, 2025, 4:05 PM EDT - 5 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 12:28 PM EDT - 7 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 16, 2025, 8:30 AM EDT - 7 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 15, 2025, 2:08 PM EDT - 7 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 8:00 AM EDT - 7 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jun 3, 2025, 8:15 AM EDT - 8 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 6, 2025, 8:00 AM EDT - 9 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 10 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 17, 2025, 8:00 AM EDT - 10 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 11 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 20, 2025, 7:30 AM EDT - 11 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 18, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 11, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 28, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 7, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 26, 2024, 7:51 AM EST - 1 year ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 16, 2024, 12:15 PM EST - 1 year ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

TrdrBuckNKy Feb. 9 at 9:10 PM

1 · Reply

Everydayhustling Feb. 9 at 5:22 PM

$KAPA when is this thing gonna pop?

1 · Reply

Xtracked Feb. 8 at 7:19 PM

$KAPA Happy SBS! I'm east coast but fk the Pats right? Either way , I believe this is the week for news!:) The breadcrumbs lead to mid Feb.... It is time ...we have felt enough pain

1 · Reply

marione Feb. 6 at 8:14 PM

$KAPA BUY BUY BUY

0 · Reply

marione Feb. 6 at 8:02 PM

0 · Reply

marione Feb. 6 at 7:58 PM

0 · Reply

marione Feb. 6 at 7:53 PM

0 · Reply

GIPARK Feb. 6 at 10:17 AM

$KAPA 야!!!!! 어디가

0 · Reply

Oldshoe Feb. 5 at 11:24 PM

0 · Reply

TB85 Feb. 5 at 7:57 PM

$KAPA I've had 5 new gray hairs, since we last got news. Maybe I'll go totaly bald on this. Sorry, I'll stop whining. But just one question, when news??

0 · Reply

TB85 Feb. 5 at 7:28 PM

$KAPA Back to ATL soon, if the quiet game continues!😔

0 · Reply

TB85 Feb. 5 at 7:24 PM

$KAPA

1 · Reply

BillionerOfKing Feb. 5 at 5:48 PM

$KAPA Current Stock Price: $0.63

0 · Reply

TrdrBuckNKy Feb. 5 at 1:18 PM

$KAPA I called the phone number below and you should too, One (1) employee?…., everyone listed below should be reported to the SEC and your Congressman… Kairos Pharma, Ltd. 2355 Westwood Boulevard Suite 139 Los Angeles, CA 90064 United States 310-948-2356 https://kairospharma.com The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California Full Time Employees: 1 https://www.sec.gov/submit-tip-or-complaint/report-possible-securities-law-violations#:~:text=SEC.gov%20%7C%20Report%20Possible%20Securities%20Law%20Violations Dr. John S. Yu M.D., Ph.D. CEO, Chairman & Secretary Mr. Douglas W. Samuelson CPA Chief Financial Officer Dr. Neil A. Bhowmick Ph.D. Chief Scientific Officer Dr. Ramachandran Murali Ph.D. Vice Pres. Research & Development

1 · Reply

Warrent_jr Feb. 5 at 8:58 AM

$KAPA

0 · Reply

GIPARK Feb. 5 at 1:19 AM

$KAPA 아무도 뭐 말도 안하네 소식도 없고.. ㅎ

1 · Reply

TrdrBuckNKy Feb. 4 at 1:14 PM

$KAPA the middle of March is a long way off to linger or even drop in the .60's, to wait for a Webinar "Symposium", that typically is meaningless to the s/p...

1 · Reply

ezcheezie Feb. 4 at 4:01 AM

$KAPA not sure of everyone has seen it yet.

0 · Reply

Xtracked Feb. 3 at 11:29 PM

$KAPA My opinion as well:) Quiet period about finished.

1 · Reply

TrdrBuckNKy Feb. 3 at 9:45 PM

$KAPA Lots of selling volume right at close today...no news, no FDA anything, no corporate location of any kind, bewildering out-going voicemail message listed on the website (and Yahoo and Google), no response from email efforts,...doesn't look promising at all...

0 · Reply

uptrend2025 Feb. 3 at 7:19 PM

$KAPA News soon here IMO

0 · Reply

Xtracked Feb. 3 at 5:29 PM

$KAPA Right place, right time...I don't think you'll have to wait very long 😜

0 · Reply

Market Cap	12.81M
Revenue (ttm)	0.00
Net Income (ttm)	-2.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	19,000
Avg Vol	157,808
Day's Range	N/A - N/A
Shares Out	20.82M
Stochastic %K	17%
Beta	2.27
Analysts	Strong Sell
Price Target	$8.33